source
- Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel PharmaceuticalsArvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…
- Capsida Biotherapeutics still unable to determine cause of child death in brain-targeted gene therapy trialCapsida Biotherapeutics reported that it still has no explanation for the death of a child who participated in its CAP-002 gene therapy trial last September. The trial was intended to test a new c…